Using Zinc Finger Nucleases to Stimulate Gene Targeting in HSC
Using Zinc Finger Nucleases to Stimulate Gene Targeting in HSC
批准号:
7569407
负责人:
Matthew H Porteus
金额:
$34.3万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-02-01 至 2010-01-31
关键词:
AdenineAmino AcidsAutologousBackBiological AssayBiologyCD34 geneCell LineCell NucleusCellsCodon NucleotidesCollaborationsDNA DamageDNA Double Strand BreakDataDiseaseDisease susceptibilityDouble Strand Break RepairEmbryoFibroblastsFundingGene TargetingGenesGeneticGenetic DeterminismGenomeGlobinGoalsHematopoietic SystemHematopoietic stem cellsHereditary DiseaseHumanHuman GeneticsIn VitroInheritedK-Series Research Career ProgramsLaboratoriesLeadLettersMarinesMeasuresMediatingMedicalMedicineMentorsMethylcelluloseModelingMusMutateMutationNOD/SCID mouseNucleic AcidsPatientsPopulationPrincipal InvestigatorProcessProcessed GenesReporterReporter GenesResearch PersonnelSickle Cell AnemiaSiteSolutionsStaining methodStainsStem cell transplantStem cellsTestingTherapeuticThymineToxic effectTransgenic MiceTransgenic OrganismsTransplantationZinc Fingersanimal model developmentbasecytotoxiccytotoxicitydesigndisease-causing mutationendonucleasegene correctionhomologous recombinationmammalian genomemedical schoolsmouse modelnucleasepluripotencyreconstitutionresearch studyresponseself-renewaltherapeutic developmenttool
中文摘要
遗传性单基因疾病渗透到医学中。在基因组时代的黎明,我们的
对遗传基因差异对疾病易感性的贡献的理解仅仅是
越来越多。镰状细胞病,第一种由氨基酸和核酸引起的单基因疾病
基因突变已被识别,并警告说,了解一种疾病的遗传原因并不容易导致
治疗。有几种潜在的方法可以在基因组水平上治疗遗传病。
一种特别有趣的方法是通过纠正导致疾病的突变来治愈这些疾病
疾病。对于镰状细胞病来说,这需要将突变的胸腺嘧啶转化回腺嘌呤。
在p-珠蛋白基因的第6密码子中插入到造血干细胞中,然后取回正确的干细胞
细胞移植给病人,就像自体干细胞移植一样。在过去的几年里,两个主要的
进展使通过基因打靶进行基因校正的可能性变得更有希望。第一个是
发现目标基因中的DNA双链断裂可以刺激基因靶向。我们
有研究发现,这种刺激最高可达5万倍。第二个是我们发现锌的模型
手指核酸酶可以通过在哺乳动物体内产生双链断裂来刺激基因靶向
基因组和我们的初步结果表明锌指核酸酶可以被设计成
刺激针对内源序列的基因靶向。双链断裂研究的下一步
介导性基因打靶是在原代细胞而不是细胞系中研究这一过程。这项建议
目的研究基因打靶过程及锌指核酸酶在造血中的应用
祖细胞。这些研究的目的都是为了了解这些基因打靶的生物学。
细胞,并利用这一理解开发靶向作为治疗单基因
镰状细胞病等疾病。
英文摘要
Inherited monogenic diseases permeate medicine. At the dawn of the genome era, our
understanding of the contribution of inherited genetic differences to disease susceptibility is only
increasing. Sickle cell disease, the first monogenic disease for which the amino acid and nucleic acid
mutations were identified, cautions that knowing the genetic cause of a disease does not easily lead to
therapies. There are several potential approaches to treating genetic diseases at the genome level.
A particularly intriguing approach is to cure such diseases by correcting the mutation that causes the
disease. For sickle cell disease this would entail converting the mutated thymine back to an adenine
in codon 6 of the p-globin gene in hematopoietic stem cells and then retrieving the corrected stem
cells to the patient as in an autologous stem cell transplant. In the last several years, two major
advances have made the possibility of gene correction by gene targeting more promising. The first is
the discovery that a DMA double-strand break in the target gene can stimulate gene targeting. We
have found that the stimulation can be up to 50,000 fold. The second is our discovery that model zinc
finger nucleases can stimulate gene targeting by creating double-strand breaks in the mammalian
genome and our preliminary results demonstrating that zinc finger nucleases can be designed to
stimulate gene targeting at endogenous sequences. The next step in the study of double-strand break
mediated gene targeting is to study the process in primary cells rather than cell lines. This proposal
aims to study the process of gene targeting and the use of zinc finger nucleases in hematopoietic
progenitor cells. The goal of these studies is both to understand the biology of gene targeting in these
cells and to use that understanding to develop targeting as a therapeutic tool to treat monogenic
diseases such as sickle cell disease.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pgen.1000376
发表时间:
2009-02
期刊:
PLoS genetics
影响因子:
4.5
作者:
[Pruett-Miller SM, Reading DW, Porter SN, Porteus MH]
通讯作者:
Porteus MH
Expanding the Repertoire of Target Sites for Zinc Finger Nuclease-mediated Genome Modification.
扩展锌指核酸酶介导的基因组修饰的靶位点库。
DOI:
10.1038/mtna.2013.13
发表时间:
2013
期刊:
Molecular therapy. Nucleic acids
影响因子:
--
作者:
[Wilson,KimberlyA, McEwen,AbbyeE, Pruett-Miller,ShondraM, Zhang,Jiuli, Kildebeck,EricJ, Porteus,MatthewH]
通讯作者:
Porteus,MatthewH
Homologous Recombination Mediated Gene Correction for the Hemoglobinopathies
-
批准号:9982120
-
项目类别:
-
资助金额:$39.53万
-
财政年份:2018
-
负责人:Matthew H Porteus
-
依托单位:
Homologous Recombination Mediated Gene Correction for the Hemoglobinopathies
-
批准号:10213813
-
项目类别:
-
资助金额:$39.53万
-
财政年份:2018
-
负责人:Matthew H Porteus
-
依托单位:
Genome Editing by Homologous Recombination to Create HIV Resistant Immune System
-
批准号:9130095
-
项目类别:
-
资助金额:$40.03万
-
财政年份:2015
-
负责人:Matthew H Porteus
-
依托单位:
Genome Editing by Homologous Recombination to Create HIV Resistant Immune System
-
批准号:8993696
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2015
-
负责人:Matthew H Porteus
-
依托单位:
Genome Editing by Homologous Recombination to Create HIV Resistant Immune System
-
批准号:9904901
-
项目类别:
-
资助金额:$8.75万
-
财政年份:2015
-
负责人:Matthew H Porteus
-
依托单位:
Pre-Clinical Development of Nuclease Mediated Gene Therapy for SCID
-
批准号:8438250
-
项目类别:
-
资助金额:$36.57万
-
财政年份:2012
-
负责人:Matthew H Porteus
-
依托单位:
Pre-Clinical Development of Nuclease Mediated Gene Therapy for SCID
-
批准号:9173450
-
项目类别:
-
资助金额:$39.44万
-
财政年份:2012
-
负责人:Matthew H Porteus
-
依托单位:
Pre-Clinical Development of Nuclease Mediated Gene Therapy for SCID
-
批准号:8581640
-
项目类别:
-
资助金额:$39.03万
-
财政年份:2012
-
负责人:Matthew H Porteus
-
依托单位:
Pre-Clinical Development of Nuclease Mediated Gene Therapy for SCID
-
批准号:8777046
-
项目类别:
-
资助金额:$39.17万
-
财政年份:2012
-
负责人:Matthew H Porteus
-
依托单位:
Development of gene targeting in C. elegans and D. rerio using zinc finger
-
批准号:7085142
-
项目类别:
-
资助金额:$17.55万
-
财政年份:2006
-
负责人:Matthew H Porteus
-
依托单位:
Development of gene targeting in C. elegans and D. rerio using zinc finger
-
批准号:7244094
-
项目类别:
-
资助金额:$17.04万
-
财政年份:2006
-
负责人:Matthew H Porteus
-
依托单位:
Using Zinc Finger Nucleases to Stimulate Gene Targeting in HSC
-
批准号:7031839
-
项目类别:
-
资助金额:$35.33万
-
财政年份:2006
-
负责人:Matthew H Porteus
-
依托单位:
Zinc Finger Nucleases to Stimulate Gene Targeting in Hematopoietic Stem Cells
-
批准号:7172341
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2006
-
负责人:Matthew H Porteus
-
依托单位:
Using Zinc Finger Nucleases to Stimulate Gene Targeting in HSC
-
批准号:7343223
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2006
-
负责人:Matthew H Porteus
-
依托单位:
The Genetics of Gene Targeting in Vertebrate Cells
-
批准号:6748089
-
项目类别:
-
资助金额:$12.42万
-
财政年份:2002
-
负责人:Matthew H Porteus
-
依托单位:
The Genetics of Gene Targeting in Vertebrate Cells
-
批准号:6891295
-
项目类别:
-
资助金额:$12.42万
-
财政年份:2002
-
负责人:Matthew H Porteus
-
依托单位:
The Genetics of Gene Targeting in Vertebrate Cells
-
批准号:6623498
-
项目类别:
-
资助金额:$12.42万
-
财政年份:2002
-
负责人:Matthew H Porteus
-
依托单位:
The Genetics of Gene Targeting in Vertebrate Cells
-
批准号:6466371
-
项目类别:
-
资助金额:$12.62万
-
财政年份:2002
-
负责人:Matthew H Porteus
-
依托单位:
The Genetics of Gene Targeting in Vertebrate Cells
-
批准号:7060896
-
项目类别:
-
资助金额:$12.42万
-
财政年份:2002
-
负责人:Matthew H Porteus
-
依托单位:
海外基金